Biologics & Advanced Therapies

Biologics & Advanced Therapies spans biotech medicines (monoclonal antibodies, recombinant proteins, vaccines), cell and gene therapies, and human tissue and blood products. These are manufactured from living systems, so quality turns on characterisation, viral safety, and control of an inherently variable biological process — a step up in complexity from small molecules.

Governed by FDA (CBER; 21 CFR 210/211 plus 1271 for HCT/Ps and 606 for blood), EU GMP Annex 2 for biological products, and the ICH Q5-series (viral safety, stability, comparability) and Q6B. Advanced therapies add cell/gene-specific expectations, and comparability after process change is a defining regulatory theme.

Testing cell lines and raw materials, and demonstrating the process clears or inactivates virus (ICH Q5A) — the safety backbone of any cell-line-derived product.

Defining the product’s quality attributes and proving comparability after any process or site change, since the process largely defines the product.

Sterile drug-substance and drug-product handling plus the cold chain that protects labile biologics from manufacture to patient.

Donor eligibility, chain-of-identity/custody, and the HCT/P and blood-product controls unique to living therapeutics.

• ›Adventitious agent or bioburden contamination of the process
• ›Loss of comparability after a process or scale change
• ›Chain-of-identity or chain-of-custody breaks in cell/gene therapy
• ›Cold-chain excursions degrading a labile product

Derived from the 38 standards SPEQ decodes for this industry.